Related Experiment Video
Updated: Apr 9, 2026

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
Published on: June 9, 2022
Hepatitis C virus drug resistance-associated substitutions: State of the art summary
Erik Lontok1, Patrick Harrington2, Anita Howe3
1Forum for Collaborative HIV Research, University of California at Berkeley, Washington, DC.
Unlabelled:
Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of interferon-free, all-oral combinations of direct-acting antivirals. While the new regimens are potent and highly efficacious, the full clinical impact of HCV drug resistance, its implications for retreatment, and the potential role of baseline resistance testing remain critical research and clinical questions. In this report, we discuss the viral proteins targeted by HCV direct-acting antivirals and summarize clinically relevant resistance data for compounds that have been approved or are currently in phase 3 clinical trials.
Conclusion:
This report provides a comprehensive, systematic review of all resistance information available from sponsors' trials as a tool to inform the HCV drug development field.
Related Concept Videos
Hepatitis
Retrovirus Life Cycles
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Treatment Resistant Cancers
Viral Mutations
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

